Skip to main content

Table 1 Characteristics of 13 patients with COVID-19

From: Effect of favipiravir and an anti-inflammatory strategy for COVID-19

Characteristics Value
Age, mean (SD), years 63 (12)
Male sex, No. (%) 9 (69)
Body weight, mean (SD), kg 70 (21)
Bronchial asthma No. (%) 1 (8)
Diabetes mellitus, No. (%) 7 (54)
Hypertension, No. (%) 8 (62)
Sleep apnea syndrome, No. (%) 3 (23)
APACHE II score, median [IQR] 9 [5, 13]
PaO2/FIO2 ratio at intubation, mean (SD) 210 (73)
D-dimer on admission, median [IQR], ng/mL 1.3 [1.0, 2.8]
CRP on admission, median [IQR], mg/dL 11.9 [4.6, 19.6]
PCT on admission, median [IQR], ng/mL 0.21 [0.09, 0.54]
Presepsin on admission, median [IQR], pg/mL 440 [302, 763]
IL-6 on admission, median [IQR], pg/mL 77.5 [35.7, 161.9]
Time from first symptom appearance, mean (SD), day
 Favipiravir 8.7 (2.6)
 Heparin 10.8 (3.9)
 Steroid 13.2 (2.9)
 Dexmedetomidine 10.7 (4.1)
 Intubation 9.9 (3.3)
ECMO, No. (%) 1 (8)
Ventilator days, median [IQR], days 11 [9, 12]
Outcome, No. (%)
 Survived 12 (92)
 Dead 1 (8)
  1. SD standard deviation, APACHE II Acute Physiology and Chronic Health Evaluation II, IQR interquartile range, PaO2 arterial partial pressure of oxygen, FIO2 fraction of inspiratory oxygen, CRP C-reactive protein, PCT procalcitonin, IL-6 interleukin-6, ECMO extracorporeal membrane oxygenation
  2. Continuous variables were reported as median [interquartile range] (IQR). Categorical variables were reported as numbers and percentages